RxDoctor Payments Data

Brian Litch, DO

Cardiovascular Disease · Mount Clemens, MINPI 1538141262

Payments from drug & device makers

$4,646in general payments, 2019–2025

Across 198 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$963
  • Kestra Medical Technology Services, Inc.$503
  • E.r. Squibb & Sons, L.L.C.$402
  • Johnson & Johnson$354
  • Novartis$343
  • Angiodynamics, Inc.$264
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,44896%
  • Education$1984%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,646 in reported general payments places this provider in the 55th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$110,845
Medicare patients
1,417
Services billed
3,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban136$171,768
XareltoRivaroxaban123$118,898
Repatha SureclickEvolocumab20$18,246
Repatha SyringeEvolocumab13$15,686
EntrestoSacubitril/Valsartan13$14,447
BrilintaTicagrelor16$14,422
Diltiazem 24hr Er (Cd)Diltiazem Hcl118$5,611
Metoprolol Succinate237$3,830
ClopidogrelClopidogrel Bisulfate133$2,825
Ranolazine ErRanolazine22$1,892
Atorvastatin Calcium117$1,463
Digoxin42$1,407
Losartan Potassium74$1,233
Carvedilol82$1,168
SotalolSotalol Hcl53$1,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$161$171,768136 claims
Johnson & JohnsonXarelto$354$118,898123 claims
NovartisEntresto$343$14,44713 claims
AstraZenecaBrilinta$104$14,42216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Mount Clemens

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →